Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
Key Details
- 1Researchers analyzed data from 109 multiple myeloma patients undergoing stem cell mobilization.
- 2Machine learning models identified time periods with low risk for serious side effects during therapy.
- 3Models could accurately predict the timing and occurrence of certain side effects in individual patients.
- 4Enables more patients to safely undergo chemotherapy and stem cell mobilization as outpatients.
- 5Outpatient treatment improves quality of life and allows for better hospital resource management.
- 6Findings published in npj Digital Medicine by Göttingen and Bielefeld researchers.
Why It Matters
By accurately stratifying patient risk using AI, more multiple myeloma patients could receive therapy outside the hospital, reducing healthcare costs and improving patient experience. This study highlights the growing role for AI in personalizing oncology care pathways.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.